Articles By Antoni Chan, MD, PhD

uveitis eye iritis

New Insights into Uveitis in Spondyloarthritis

By Antoni Chan, MD, PhD

Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute episode of uveitis develop recurrent anterior uveitis or iritis.

Read Article
uveitis eye iritis

New Insights into Uveitis in Spondyloarthritis

By Antoni Chan, MD, PhD

Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute episode of uveitis develop recurrent anterior uveitis or iritis.

Read Article
Puzzle pieces

Axial spondyloarthritis with psoriasis or psoriatic spondylitis

By Antoni Chan, MD, PhD

PsA commonly affects peripheral joints. In up to a quarter of PsA patients, the spine may be involved and this is known as psoriatic spondylitis (PsSpA). An important research question is whether PsSpA and Axial Spondyloarthritis (AxSpA) with psoriasis are separate conditions or not. 

Read Article
journal book learning study meeting notes

Excited About ACR Convergence 2020

By Antoni Chan, MD, PhD

I always think of why I attend the ACR: to gain new information and knowledge and bring it back to my clinic for my patients. Here's what I'm looking forward to this year.

Read Article
Xeljanz4.jpg

Spondyloarthritis at ACR Convergence 2020

By Antoni Chan, MD, PhD

There are some really interesting poster and abstract presentations on spondyloarthritis at the ACR Convergence 2020. I’ll be covering these topics, and discussing select individual posters and abstracts during this meeting. 

Read Article
fitness-3448864_640.jpg

New Treatments in Axial SpA from #ACR2019

By Antoni Chan, MD, PhD

There were new developments in the treatment of axial Spondyloarthritis (AS) at ACR 2019. The first area is on the use of anti-IL17A drugs, secukinumab and ixekizumab in non-radiographic AS. The second area is the use of JAK-1 inhibitor Upadacitinib in radiographic AS.

Read Article
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Profile picture for user Antoni Chan, MD, PhD
  • Antoni Chan, MD, PhD

  • Prof. Antoni Chan, PhD, FRCP, is Consultant Rheumatologist, Professor and Head of Rheumatology at the Royal Berkshire NHS Foundation Trust, Reading, United Kingdom. He is a also a specialist physician with a broad interest in internal medicine. He has been on the faculty of RheumNow since 2019. His specialist area of research is in spondyloarthropathies and digital healthcare technologies including artificial intelligence. He is a full member of ASAS and GRAPPA. He is on the working group of the British Society for Rheumatology (BSR) axSpA biologics guideline group. He won the BSR Best Practice Award in 2016 and 2024 for an innovative pain management and primary care educational programme. In 2018 he received the Patient Choice Award for Best Care by a Rheumatologist and in 2023 the Gold Changemaker Award from the National Axial Spondyloarthritis Society (NASS) UK. He leads the Axial Spondyloarthritis service in his hospital and his team have published their work on reducing delay to diagnosis in this condition. Follow him on X @synovialjoints.

×